Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
A phase 1 clinical trial evaluating marizomib, pomalidomide and low‐dose dexamethasone in relapsed and refractory multiple myeloma (<scp>NPI</scp>‐0052‐107): final study results
Andrew Spencer, Simon J. Harrison, Jeffrey A. Zonder, Ashraf Badros, Jacob P. Laubach, Krystal Bergin, Amit Khot, Todd M. Zimmerman, Dharminder Chauhan, Nancy K. Levin, Ann MacLaren, Steven D. Reich, Mohit Trikha, Paul G. Richardson (2017). A phase 1 clinical trial evaluating marizomib, pomalidomide and low‐dose dexamethasone in relapsed and refractory multiple myeloma (<scp>NPI</scp>‐0052‐107): final study results. , 180(1), DOI: https://doi.org/10.1111/bjh.14987.
Article278 days agoPmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label Study
Andrew Spencer, Simon J. Harrison, Jacob P. Laubach, Jeffrey A. Zonder, Ashraf Badros, Krystal Bergin, Amit Khot, Todd M. Zimmerman, Kenneth C. Anderson, Ann MacLaren, Steven D. Reich, Mohit Trikha, Paul G. Richardson (2016). Pmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label Study. , 128(22), DOI: https://doi.org/10.1182/blood.v128.22.3326.3326.
Article278 days agoPhase 1, Multicenter, Open-Label, Combination Study (NPI-0052-107; NCT02103335) of Pomalidomide (POM), Marizomib (MRZ, NPI-0052), and Low-Dose Dexamethasone (LD-DEX) in Patients with Relapsed and Refractory Multiple Myeloma
Andrew Spencer, Jacob P. Laubach, Jeffrey A. Zonder, Ashraf Badros, Simon J. Harrison, Amit Khot, Dharminder Chauhan, Kenneth C. Anderson, Steven D. Reich, Mohit Trikha, Paul G. Richardson (2015). Phase 1, Multicenter, Open-Label, Combination Study (NPI-0052-107; NCT02103335) of Pomalidomide (POM), Marizomib (MRZ, NPI-0052), and Low-Dose Dexamethasone (LD-DEX) in Patients with Relapsed and Refractory Multiple Myeloma. , 126(23), DOI: https://doi.org/10.1182/blood.v126.23.4220.4220.
Article278 days agoSubcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study
Nizar J. Bahlis, Jeffrey A. Zonder, Lionel Karlin, Torben Plesner, Laura París, Tomasz Wróbel, Vânia Hungria, Britta Besemer, Edvan Crusoé, Trine Silkjær, Aurore Perrot, Philippe Moreau, Ka Lung Wu, Sosana Delimpasi, Meletios A Dimopoulos, Mark‐David Levin, Silvia Mangiacavalli, Ivo Nnane, Yu Jin Kim, Maria Krevvata, Linlin Sha, Susan Wróblewski, Alba Tuozzo, Robin Carson, Thierry Facon (2025). Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study. , 66(14), DOI: https://doi.org/10.1080/10428194.2025.2561117.
Article23 days agoPhase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma
Meletios A Dimopoulos, Magdalini Migkou, Manisha Bhutani, Sikander Ailawadhi, Anna Kalff, Farzana L. Walcott, Nabendu Pore, Miranda Brown, Fujun Wang, Lily Cheng, Ioannis Kagiampakis, Marna Williams, Krista Kinneer, Yuling Wu, Yu Jiang, Robert Kubiak, Jeffrey A. Zonder, Jeremy T. Larsen, Shreerang Sirdesai, Andrew J. Yee, Shaji Kumar (2024). Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma. , 65(12), DOI: https://doi.org/10.1080/10428194.2024.2373331.
Article23 days ago